PL3362449T3 - Pochodne sybiriliny do zastosowania do zapobiegania i/lub leczenia zaburzeń związanych z nekroptozą komórkową - Google Patents

Pochodne sybiriliny do zastosowania do zapobiegania i/lub leczenia zaburzeń związanych z nekroptozą komórkową

Info

Publication number
PL3362449T3
PL3362449T3 PL16781455T PL16781455T PL3362449T3 PL 3362449 T3 PL3362449 T3 PL 3362449T3 PL 16781455 T PL16781455 T PL 16781455T PL 16781455 T PL16781455 T PL 16781455T PL 3362449 T3 PL3362449 T3 PL 3362449T3
Authority
PL
Poland
Prior art keywords
preventing
disorders associated
treating disorders
sibiriline
derivatives
Prior art date
Application number
PL16781455T
Other languages
English (en)
Inventor
Marie-Thérèse DIMANCHE-BOITREL
Stéphane BACH
Claire DELEHOUZE
Yvette Mettey
Peter Goekjian
Arnaud COMTE
Original Assignee
Institut National De La Santé Et De La Recherche Médicale (Inserm)
Centre National De La Recherche Scientifique (Cnrs)
Universite De Poitiers
Sorbonne Université
Universite Claude Bernard Lyon 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National De La Santé Et De La Recherche Médicale (Inserm), Centre National De La Recherche Scientifique (Cnrs), Universite De Poitiers, Sorbonne Université, Universite Claude Bernard Lyon 1 filed Critical Institut National De La Santé Et De La Recherche Médicale (Inserm)
Publication of PL3362449T3 publication Critical patent/PL3362449T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
PL16781455T 2015-10-13 2016-10-13 Pochodne sybiriliny do zastosowania do zapobiegania i/lub leczenia zaburzeń związanych z nekroptozą komórkową PL3362449T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306624 2015-10-13
PCT/EP2016/074638 WO2017064217A1 (en) 2015-10-13 2016-10-13 Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis
EP16781455.7A EP3362449B1 (en) 2015-10-13 2016-10-13 Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis

Publications (1)

Publication Number Publication Date
PL3362449T3 true PL3362449T3 (pl) 2021-12-13

Family

ID=54337712

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16781455T PL3362449T3 (pl) 2015-10-13 2016-10-13 Pochodne sybiriliny do zastosowania do zapobiegania i/lub leczenia zaburzeń związanych z nekroptozą komórkową

Country Status (6)

Country Link
US (1) US10426758B2 (pl)
EP (1) EP3362449B1 (pl)
DK (1) DK3362449T3 (pl)
ES (1) ES2885474T3 (pl)
PL (1) PL3362449T3 (pl)
WO (1) WO2017064217A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3788045T3 (pl) 2018-05-03 2023-10-09 Rigel Pharmaceuticals, Inc. Związki hamujące rip1 oraz sposoby ich wytwarzania i wykorzystania
SI3788044T1 (sl) 2018-05-03 2023-12-29 Rigel Pharmaceuticals, Inc. Spojine, ki zavirajo RIP1 in postopki za njihovo izdelavo in uporabo
CN111978311B (zh) * 2019-05-21 2024-05-31 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
AU2020341708B2 (en) 2019-09-06 2024-01-04 Rigel Pharmaceuticals, Inc. RIP1 inhibitory compounds and methods for making and using the same
ES3043457T3 (en) 2019-09-06 2025-11-25 Rigel Pharmaceuticals Inc Rip1 inhibitory compounds and methods for making and using the same
SMT202600151T1 (it) 2019-11-07 2026-05-12 Rigel Pharmaceuticals Inc Composti eterociclici inibitori di rip1
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k
TWI824259B (zh) 2020-07-01 2023-12-01 美商雷傑製藥公司 Rip1k抑制劑
US20240116923A1 (en) * 2021-01-25 2024-04-11 Seabelife Use of indole, 6- and 7-azaindole derivatives as inhibitors of ferroptosis regulated cell death
TW202300490A (zh) 2021-03-11 2023-01-01 美商雷傑製藥公司 雜環rip1激酶抑制劑
EP4626414A1 (en) 2022-12-02 2025-10-08 Seabelife Synergistic combinations of regulated necrosis inhibitors with n-acetylcysteine
EP4791394A1 (en) 2023-10-12 2026-08-19 Seabelife Method and kit for inducing cell differentiation, and regulated necrotic cell death inhibitor for use for regenerating damaged tissues

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
AU2004315596B2 (en) 2003-08-29 2011-11-24 President And Fellows Of Harvard College Inhibitors of cellular necrosis
JP5244118B2 (ja) * 2006-11-10 2013-07-24 ブリストル−マイヤーズ スクイブ カンパニー 新規キナーゼ阻害剤
WO2011140164A1 (en) * 2010-05-06 2011-11-10 Merck Sharp & Dohme Corp. Aza-indole derivatives useful as modulators of faah
ME03000B (me) 2012-12-21 2018-10-20 Plexxikon Inc Jedinjenja i metode modulacije kinaze i povezane indikacije
TW201613916A (en) * 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
EP3362450B1 (en) * 2015-10-13 2020-07-01 Institut National de la Sante et de la Recherche Medicale (INSERM) N1- and n7-substituted sibiriline derivatives and their use as inhibitors of cellular necroptosis

Also Published As

Publication number Publication date
ES2885474T3 (es) 2021-12-13
US20180325876A1 (en) 2018-11-15
EP3362449A1 (en) 2018-08-22
EP3362449B1 (en) 2021-06-16
WO2017064217A1 (en) 2017-04-20
US10426758B2 (en) 2019-10-01
DK3362449T3 (da) 2021-07-19

Similar Documents

Publication Publication Date Title
IL256501B (en) Causes, uses and methods of treating synuclein pathology
IL256874B (en) Immune checkpoint suppressors for use in the treatment of blood-borne cancers
IL259570A (en) Combined therapy and their uses and methods
IL255780A (en) Therapeutic combinations and methods for treating neoplasia
IL253656A0 (en) Mono- and polyazanephthalene modified histories and their use
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
SMT202300166T1 (it) Antagonisti di attivina- actrii e usi per il trattamento di sindrome mielodisplastica
IL252560A0 (en) Heterocyclic derivatives and their uses
GB2588261B (en) Apparatus, use of the apparatus and arrangement
DK3362449T3 (da) Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose
GB201512733D0 (en) Therapeutic agents for treating conditions associated with elevated GDF15
IL257820A (en) Aminoglycosides for the treatment of genetic diseases
IL271728A (en) Materials, uses and treatment methods
ZA201604611B (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
PT3166945T (pt) Derivados de triazolopirimidinona ou de triazolopiridinona inovadores e utilização dos mesmos
SG10201912843YA (en) Sleep improving agent
ZA202002526B (en) New alcoxyamino derivatives for treating pain and pain related conditions
PL3386988T3 (pl) Nowe pochodne dihydropiranopirymidynonu i ich zastosowanie
PT3268356T (pt) Compostos heterocíclicos e métodos para a sua utilização
SG11201610349SA (en) Dosing regimens for treating and/or preventing cerebral amyloidoses
IL255012A0 (en) Preparations and methods for treating skin conditions
GB2545167B (en) Cloches and use thereof
GB201500278D0 (en) Novel combination and use
AU2014903677A0 (en) Treating and/or preventing psoriasis